Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

New NOTIFY Nurse Call app release features major communications and functionality enhancements, and customizations


News Image

“We continue to work tirelessly to make NOTIFY Nurse Call the nation’s leading nurse call and communications system and our newest features really will help communities communicate better, work more efficiently and provide top-tier care to residents,” said NOTIFY General Manager Greg Robertson.

NOTIFY announced today the version 1.5 release of its Nurse Call mobile app, now available in both the Android and iOS app stores. The latest version marks the most significant and robust update to date and includes key functionalities to make the app even more seamless and actionable.

The latest enhancements include:


  • Push to Talk: The addition of Push to Talk allows caregivers to simply press a button, talk and deliver a message to one or all other caregivers. This real-time voice communication is network agnostic, works from anywhere and allows caregivers to eliminate the expensive, unreliable hardware that they normally are forced to utilize.
  • Group Chat and Group Text: Users have the ability to text message other caregivers either individually or as a group inside the app, making it native and secure.
  • Zone Escalation: Zone escalation now allows alerts to be escalated via text message, email, pager or inside the app. There are also enhanced customizations now available to direct where alerts go, where they’re delivered and at what times.
  • Alert Reason Capture: Caregivers can now track how many alerts are health-related or not, allowing for improved workforce efficiencies and resident services.

NOTIFY Nurse Call 1.5 also includes technical improvements and enhancements to help fine-tune and streamline server synchronization, time zone configurations and more.

The release fully integrates with NOTIFY’s Dashboards in order help users dig deeper into the data to provide communities with documentation and accountability and drive workforce efficiencies.

“We’re thrilled to be able to offer these latest upgrades and functionalities to our customers,” said NOTIFY General Manager Greg Robertson. “We continue to work tirelessly to make NOTIFY Nurse Call the nation’s leading nurse call and communications system and our newest features really will help communities communicate better, work more efficiently and provide top-tier care to residents.”

ABOUT NOTIFY: NOTIFY Nurse Call is a next generation mobile nurse call solution that allows your caregivers to receive and respond to alerts from wherever they are in the building. Give your staff the tools they need to provide optimal care—and give your senior community the real-time data needed to staff appropriately, assess performance and improve accountability. Utilizing world-renowned, non-proprietary Inovonics technology, NOTIFY is a complete wireless alert system solution that provides real-time communication across the full spectrum of your operation.

For further information, please contact: Greg Robertson, Senior VP/General Manager, NOTIFY: grobertson@notifync.com, (844) 666-3039

Follow NOTIFY on LinkedIn / Facebook / YouTube

Share article on social media or email:

Makers Nutrition Wins People’s Choice Stevie® Award in 2020 International Business Awards®


Makers Nutrition wins three People’s Choice Stevie® Awards for Favorite Companies in The 17th Annual International Business Awards®.

The winners of the People’s Choice Stevie Awards were able to activate and motivate their customers, employees, social media followers and other constituents to vote for them, and that is a testament to the healthy ties they have to those audiences.

Makers Nutrition was named a winner of three People’s Choice Stevie® Awards for Favorite Companies in The 17th Annual International Business Awards®.

The International Business Awards are the world’s premier business awards program. All organizations worldwide are eligible to submit nominations – public and private, for-profit and non-profit, large and small.

The winners of the crystal People’s Choice Stevie Awards will be celebrated during a virtual awards ceremony for the 2020 IBAs on Tuesday, 1 December.

The People’s Choice Stevie Awards for Favorite Companies are an annual feature of The International Business Awards. The worldwide public vote was conducted over the past month, with the highest number of votes deciding the winners in a variety of industry categories. More than 43,000 votes were cast. To win, a category’s leading vote-getter had to receive at least 100 votes.

All organizations honored in the IBA’s Company of the Year categories were included in people’s choice voting.

More than 3,800 nominations were submitted to this year’s International Business Awards by organizations in more than 60 nations and territories, for consideration in a wide range of categories. These categories included: New Product or Service of the Year, Most Innovative Company of the Year, Management Team of the Year, Best New Product or Service of the Year, Startup of the Year and Executive of the Year, among others.

This is Makers Nutrition’s second People’s Choice Stevie in the International Business Awards. It completes the company’s biggest year for wins in the IBAs, having also been named a GRAND recipient. Makers Nutrition was named a 2020 Favorite Company in the following categories:


  • Manufacturing
  • Consumer Products
  • Other Industries

“The winners of the People’s Choice Stevie Awards were able to activate and motivate their customers, employees, social media followers and other constituents to vote for them, and that is a testament to the healthy ties they have to those audiences,” said Stevie Awards president Maggie Gallagher.

Details about The International Business Awards, the complete list of People’s Choice Stevie Award winners, and the list of all 2020 Gold, Silver, and Bronze Stevie Award winners in the IBAs are available at http://www.StevieAwards.com/IBA.

About Makers Nutrition

Makers Nutrition, an Inc. 5000 Fastest-Growing Company in America, is a groundbreaking provider for dietary supplement companies worldwide. Specializing in capsules, tablets, powders, softgels and gummies, Makers Nutrition provides a full-service option for all contract manufacturing, graphic design, packaging and fulfillment service needs.

About the Stevie® Awards

Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, the Middle East & North Africa Stevie Awards, The American Business Awards®, The International Business Awards®, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 nominations each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at http://www.StevieAwards.com

Share article on social media or email:

Dr. Jeffrey Bowman, CFA To Become MyDentalWig’s New Capital Advisor


News Image

Today, My Dental Wig, a producer of accessible premium dental products, announced they are welcoming Dr. Jeffrey Bowman, CFA as the company’s new Capital Advisor. Jeffrey Bowman’s new position will be essential in increasing capital earnings and supporting MDW’s effort to raise $15 million for its latest campaign, which aims to improve the business’s distribution of tooth-replacement solutions and subsequently see sales of more than $1 billion within a year. This early-stage dilutive capital is anticipated to see an exit of 24 to 36 months from increased revenue.

In her recent funding request pitch video, MyDentalWig founder Lydie Livolsi said, “As a company founded by a Black woman entrepreneur, MyDentalWig has been subject to the system racism that America is currently dealing with. As increased energy from corporations and individuals begin to be applied to Black-owned businesses, MyDentalWig expects to be able to benefit from additional investment not as a righting of historical wrongs, but also as a winning product with a solution to potentially millions of Americans.”

Jeffrey Bowman’s contribution to MyDentalWig is expected to propel the company to greater heights thanks to the following reasons:

  • Doctorate in Clinical Science, aligning him with MyDentalWig’s mission to produce some of the market’s finest dental health products
  • Healthcare Investment Banker and Venture Capital helping raise $800 million and exiting over $5 billion for investors
  • More than eight years of experience providing analytical support for multiple life sciences companies

MyDentalWig solves the common problem of expensive and painful dental products by providing affordable and hassle-free solutions to tooth loss. There are currently 178 million Americans with at least one missing tooth and another 249 million adults without and with dental insurance, which contributes to MDW’s sizeable capital evaluations.

As a patented and FDA approved product, MyDentalWig™ snaps into empty spaces left behind by a missing tooth/teeth, removing the need for healthy teeth to be ground down or impacted and saving a lot of money for dental bridge or implant. Wearers can continue to eat and sleep as usual with the product, making it a pain-free and straightforward alternative when compared to traditional tooth/teeth-replacement solutions. MyDentalWig will send trained and background checked technologists to the customer’s home to acquire the wearer’s teeth impressions, provide them with a trial product, and offer final delivery and adjustments.

Lydie Livolsi invented the first-ever MyDentalWig™ prototype after several years of working in a dental lab in France and running her own 2 locations of dental lab. store in Reims (city of Champagne), France, and another one in downtown Paris, France. She has since relocated to Los Angeles to expand the business further and seek out new investors.

About MyDentalWig: MyDentalWig.com is a manufacturer of accessible premium dental products based in Los Angeles County, CA. Founded by Lydie Livolsi, a Black woman entrepreneur with over 30 years of experience in dental manufacturing and practice management, MyDentalWig’s mission is to offer consumers peace of mind when dealing with tooth loss solutions. Lydie recently placed Top 5 in the Women Founders Network’s 2020 Woman Of Distinction Finalist Award and has received multi-billion USD financial projections.

Final Pitch day: November 11th, 2020 at 4:00 PM to 6:00 PM PST.

To register to watch on zoom, click here

Share article on social media or email:

New Theory Sheds Light on How the Environment Influences Human Health


Researchers at Mount Sinai have proposed a groundbreaking new way to study the interaction between complex biological systems in the body and the environment. Their theory suggests the existence of “biodynamic interfaces,” an intermediate entity between the two realms, as opposed to conventional approaches that analyze individual aspects of the interaction between the environment and humans in isolation, according to a paper published in BioEssays in October.

The environment impacts human health in profound ways, yet few theories define the form of the relationship between human physiology and the environment. The Mount Sinai scientists believe that such complex systems cannot interact directly, but rather that their interaction requires the formation of an intermediary “interface.” The scientists believe that this theory will lead to the establishment of a new field, “environmental biodynamics,” that will advance the way the environment and human health are studied.

The basis of their theory arose when they compared the time period when autistic children were exposed to toxins to how the children’s brains functioned afterward. At the same time, they found distinct patterns in the intake and metabolism of essential elements and toxins, which were dependent not only on the timing and magnitude of the environmental exposure but also on what was happening within the biological systems of the child’s body.

“These rhythms were driven by the properties of both the biological and environmental systems, but exhibited properties independent of either system,” said Manish Arora, PhD, the Edith J. Baerwald Professor and Vice Chair of Environmental Medicine and Public Health at the Icahn School of Medicine at Mount Sinai. “They supported the existence of an interface mediating the interaction of biological and environmental systems. The interface itself, which applies constraints and passes information between interacting systems, must be the subject of inquiry because without refocusing the attention on biodynamic interfaces, how the environment impacts health cannot be discerned.”

The study of the interface will allow scientists to better understand how complex systems like the environment and human physiology affect each other. Current methods using plain analysis are incomplete, the scientists say.

“The standard course of inquiry measures some aspect of the environment like lead in the water, and we’d link this to some aspect in human development like IQ,” said Paul Curtin, PhD, Assistant Professor of Environmental Medicine and Public Health at the Icahn School of Medicine at Mount Sinai, an author on the paper. “We’ve learned a lot from environmental health using this approach, but it has its limits.”

This interface also considers social, behavioral, and cultural dynamics to be a particularly fruitful avenue of research. This new theory would allow scientists to assess the interface between income and other processes, including health outcomes using dynamical systems methods. It would also define how human activities could negatively influence the environment and negatively influence their own health outcomes and further environmental impacts over time.

Dr. Arora’s work was funded by a prestigious Revolutionizing Innovative, Visionary Environmental Health (RIVER) Award from the National Institute of Environmental Health Sciences, totaling $8 million over eight years to complete research on the biodynamic interface. Alessandro Giuliani, PhD, Professor of Environmental Health at the University of Rome, has made a significant contribute to the development of the theory.

“Arora, Giuliani, and Curtin’s conjecture is potentially a major breakthrough, as knowing the factors that influence biological time may be the key to understanding why people age or mature at different rates, and how our early life experiences can influence our health as adults,” said Robert O. Wright, MD, MPH, Ethel H. Wise Professor and Chair of Environmental Medicine and Public Health and Director of the Institute for Exposomic Research at the Icahn School of Medicine at Mount Sinai.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

Transpara® Breast Care launch helps drive the worldwide adoption of AI to assist in the fight against breast cancer


News Image

www.transparabreastcare.com

“We want to make a real difference in the lives of families by reducing the impact of breast cancer and improving survival rates.”

With a shortage of breast radiologists in many countries along with a global increase in the incidence of breast cancer this upsurge in the use of AI for early detection comes at a critical time.

Transpara is the first deep learning AI system to be FDA cleared and CE marked for both 2D and 3D mammograms and it has been clinically proven to identify potential cancers earlier, to improve the accuracy of radiologists, and to help radiologists read more quickly. This decision support software uses a sophisticated algorithm that gives clinicians immediate objective feedback on areas of suspicion identified within a mammogram. This helps to speed up decision making and, more importantly, to increase accuracy of detection.

Nicki Bryan, Vice President of Sales for ScreenPoint Medical in the United States, said she is delighted to see this rapid adoption of Transpara. “We want to make a real difference in the lives of families by reducing the impact of breast cancer and improving survival rates. As more radiologists begin to use Transpara we can begin to recognize that goal.”

“We know that Transpara works with most mammography systems and we’re seeing that the software seamlessly integrates into the current workflow of the doctors using our solution. This gives us the ability to provide access to this technology to patients everywhere.” “Bryan concludes by saying, “We are using the experience and knowledge of thousands of radiologists and the data from a million+ mammograms worldwide to continuously train Transpara. Improvements are ongoing so our customers are always automatically upgraded to the newest version of Transpara. This ensures that new benefits are available without adding extra cost”.

To meet the growing demand for information about AI, Transpara now has its own website dedicated to empowering women to take charge of their breast health via education.: http://www.transparabreastcare.com

Nico Karssemeijer, CEO and founder of ScreenPoint Medical states,

“The launch of http://www.transparabreastcare.com will help to teach women about how AI can work hand in hand with their radiologist to deliver better care. Research shows that some women still feel apprehensive about trusting AI but the reality is, it should bring peace of mind. By providing clinically proven decision support to radiologists with Transpara, we aren’t replacing the radiologist, we are arming the radiologist with a powerful tool.

We started this company to help improve breast cancer survival and we work tirelessly to ensure that breast cancer can be found faster and earlier. That is what will save women’s lives.”

http://www.transparabreastcare.com is an educational website that focuses on the importance of early detection, screening mammography and the benefits of Transpara AI. Transpara® is an AI solution for breast cancer screening, that uses deep learning algorithms to automatically detect lesions suspicious for breast cancer in 2D and 3D mammograms. The software categorises mammograms on a 10-point scale indicating the degree of risk that cancer is present. This Exam Score can be used to help radiologists prioritise patients for further investigation. Decision support marks for calcifications and soft tissue lesions are provided to support radiologists with image interpretation. Studies have shown that Transpara matches the performance of radiologists thus acting as a second opinion which increases diagnostic confidence and accuracy. It is FDA cleared for 2D and 3D mammography.

Share article on social media or email:

Healthclick, a leader in online education, launches a new learning platform to deliver higher quality online continuing education to healthcare professionals


healthclick launches new physical therapy continuing education learning platform

healthclick physical therapy continuing education

Our goal is to deliver a higher quality online educational experience by leveraging our digital technologies to provide evidence-based medical content for an engaging visual experience. We focus on quality over quantity concerning continuing education courses.Tom Vastano – CEO healthclick

We are transforming the physical therapy online continuing education market with our new website, learning management system and unique technology. This new system integrates our proprietary Elomotus® muscle visualization technology into high definition video-based courses that combine medical experts, 3D animations, medical illustrations, and real patient case studies to create a world class educational experience.

By 2023, the online health education solutions market will be a $13 billion market globally. Growth in this segment mirrors cultural trends, in-person meeting restrictions due to Covid, financial factors, and improving online learning technologies.

Healthclick goes beyond just helping medical practitioners meet licensing requirements for continuing education. Comprehensive courses bring the learner to a greater understanding of complex medical topics, translating into better patient care and better management of financial resources within the healthcare system.

Check out a demo of a physical therapy continuing education course:

Gait Analysis Continuing Education

We are looking for partners to work with our team to design, create and deliver online continuing education.

Share article on social media or email:

Clinical Drug Candidate SDX-7320 Offsets Hyperglycemia Caused by PI3K/Akt/mTOR Cancer Therapies and Restores Insulin Sensitivity, SynDevRx’s Preclinical Studies Show


“Our preclinical data with alpelisib (Piqray®) and capivasertib suggests that SDX-7320 may make drugs targeting the PI3k/Akt/mTOR pathway safer and more effective by controlling blood glucose and insulin levels in combination with tumor growth inhibition.”

SynDevRx, Inc., a clinical-stage oncology company, announces the completion of a series of preclinical studies demonstrating that its anti-cancer drug candidate, SDX-7320, inhibits PI3K/Akt inhibitor-induced hyperglycemia and subsequent hyperinsulinemia in normal mice and inhibits tumor growth in multiple models of HR+ breast cancer. The company’s ongoing research places them at the vanguard of metabo-oncology, an emerging field of cancer research that focuses on the role metabolic hormones play in the development and progression of many common cancers, as well as tumor resistance developed in response to certain treatments.

SDX-7320 inhibits MetAP2, a clinically validated target that plays a key role in tumor growth, metastasis, angiogenesis, and metabolic dysfunction. In a series of efficacy and safety studies in a variety of syngeneic cancer models (breast, melanoma), SDX-7320 displayed single agent anti-tumor activity while improving metabolic dysfunction (in particular, hyperglycemia, insulin resistance and leptin resistance). [1] SDX-7320 prevented the hyperglycemia and hyperinsulinemia associated with Piqray® (Novartis’ PI3Kα inhibitor) [2] administration in normal mice – serious side effects of drugs from these classes that have been reported to lead to treatment resistance. [3] Furthermore, in a xenograft model of ER+/Her2- breast cancer, SDX-7320 and Piqray® (alpelisib), [2] administered together at low doses, showed synergy at inhibiting tumor growth.

“Piqray is an important new therapy for patients with HR+/Her2-, metastatic breast cancer whose tumors have a mutation in the PIK3CA gene. However, drugs that target the PI3K/Akt pathway frequently cause hyperglycemia in patients, especially those with high baseline fasting glucose, HbA1c, insulin resistance, pre-diabetes, type 2 diabetes or obesity. [4] Treatment-induced hyperglycemia has been reported as a safety concern that can lead to dose interruptions and/or drug holidays. In addition, the treatment-induced hyperglycemia leads to hyperinsulinemia which in pre-clinical studies has been shown to cause resistance to these drug classes.” [5] said Jim Shanahan, Co-Founder and Chief Business Officer of SynDevRx. “Baseline systemic metabolic complications, such as obesity, pre-diabetes or type 2 diabetes were reported to correlate with and predict worse outcomes for many breast cancer patients taking Piqray”. [3]

Preclinical studies of SDX-7320 with another drug from the PI3k/Akt class, the Akt/mTOR inhibitor, capivasertib (AstraZeneca) showed that SDX-7320 also attenuated treatment-induced hyperglycemia (in normal mice), and inhibited tumor growth in a xenograft model of HR+/Her2+ breast cancer. “Our preclinical data with alpelisib (Piqray®) and capivasertib suggests that SDX-7320 may make drugs targeting the PI3k/Akt/mTOR pathway safer and more effective by controlling blood glucose and insulin levels in combination with tumor growth inhibition,” he continued.

“Companies developing drugs targeting the PI3K/Akt/mTOR pathway may experience toxicity issues related to drug-induced hyperglycemia followed by hyperinsulinemia, eventually resulting in resistance to therapy. [5] SDX-7320 has demonstrated that it can help to address this problem in vivo,” said Brad Carver, Co-Founder, President and CEO of SynDevRx. “Our data suggests that drugs targeting the PI3K/Akt/mTOR pathway should see better safety and better anti-tumor activity by administering SDX-7320 in combination with those agents.”

To test this hypothesis, SynDevRx intends to commence Phase 2 studies in late-stage ER+, Her2- breast cancer patients. To learn more about SynDevRx clinical trials, visit: http://www.syndevrx.com/.

References

1. Abstract 4919: Preclinical activity of SDX-7320 in mouse models of obesity and obesity-driven cancer. Cornelius P, Petersen JS, Mayes B, Turnquist D, Sullivan K, Anderson-Villaluz A, Lutz R, Little S, Slee A, Carver BJ, Shanahan J. Cancer Res July 1 2018 (78) (13 Supplement) 4919; DOI: 10.1158/1538-7445.AM2018-4919

2. Abstract 2147: Synergistic inhibition of MCF-7 mammary gland tumor growth with Piqray®(alpelisib) plus SDX-7320, a novel polymer-conjugated methionine aminopeptidase 2 (MetAP2) inhibitor. Cornelius P, Mayes B, Little S, Slee A, Nir R, Nir A, Carver B, Shanahan J. Cancer Res February 14 2020 80 (4 Supplement) P3-11-13-P3-11-13; DOI:10.1158/1538-7445.SABCS19-P3-11-13

3. André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929-1940. doi:10.1056/NEJMoa1813904: Fox et al., Breast Cancer Research volume 15, Article number: R55 (2013)

4. Rugo et al, 2020, Annals of Oncology: https://doi.org/10.1016/j.annonc.2020.05.001

5. Hopkins, B.D., Pauli, C., Du, X. et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature 560, 499–503 (2018). https://doi.org/10.1038/s41586-018-0343-4

About SynDevRx

SynDevRx is a privately held clinical stage biopharmaceutical company based in Cambridge, Massachusetts focused on the research and development of treatments that address the unique and underserved needs of cancer patients with systemic metabolic dysfunction – i.e., metabo-oncology. Obesity, pre-diabetes and type 2 diabetes are known to worsen cancer patients’ prognosis, but oncologists have no specific tools to deal with systemic metabolic complications except for changes in diet and exercise. SynDevRx intends to initiate a series of Phase 2 clinical studies of its drug candidate SDX-7320 to address this major, unmet medical need. Preclinical studies have shown that SDX-7320 reduces tumor growth and angiogenesis, helps to control aberrant metabolic hormone signaling, and reduces treatment resistance to certain standard cancer therapies in metabolically sensitive cancers. SDX-7320 is being developed for use in combination with standard of care therapies for a variety of solid tumors.

Share article on social media or email:

DBC Ambulance Manufacturers Release Free Ambulance Decontamination White Paper


The new 16-page white paper focuses specially on Ambulance Decontamination options for infectious diseases like Covid-19.

The DBC Ambulance Decontamination white paper provides guiding principles, practical recommendations, and resources to help EMS organizations form strategies that will enhance safety for patients, responders, and our communities.

Demers-Braun-Crestline (DBC) has released a 16-page white paper titled Ambulance Decontamination: Information, Resources, & Considerations for High-Risk Infection Control in an Ambulance. Fire/EMS professionals have the opportunity to download the free white paper to learn more about best practices, and recommended solutions to integrate into their own strategic plans, as they continue to combat infectious diseases.

While the worldwide emergency response community remains on the frontlines of the COVID-19 pandemic, DBC has been busy behind the scenes dedicating engineering resources to focus on ambulance decontamination. Long committed to safety and innovation, DBC evaluated a wide range of products, design options, and protocols to help protect patients and EMS personnel from infectious diseases in an ambulance setting. That collective knowledge was organized into the new white paper, which contains information, resources, and recommendations on ambulance infectious disease control measures. It should serve as an introductory guide for organizations overwhelmed by where to start with ambulance decontamination.

The 16-page white paper answers several important questions, but centers on one primary topic: What feature and design considerations should be reviewed inside an ambulance? Identifying five key areas, each section educates readers on ambulance options and features that assist in limiting the spread of viruses, bacteria, parasites, and fungi. From plexiglass dividers to HEPA filters, chemical fogging systems to self-disinfecting surfaces, and everything in-between, the white paper outlines a variety of solutions that every emergency response organization should consider for enhancing safety inside their ambulances.

Prior to the public release of the document, Demers-Braun-Crestline provided advance copies to two well-known leaders in EMS, AJ Heightman and Chief Randy Mellow. AJ Heightman, Editor Emeritus at JEMS (Journal of Emergency Medical Services) and Adjunct Instructor of Clinical Research and Leadership at George Washington University School of Medicine and Health Sciences, said, “Demers-Braun-Crestline has been one of the leaders in our industry for over 100 years, presenting customers with innovations, special design and safety features, and options. This white paper is another example of their thought leadership – focusing on management and the elimination of infectious diseases in ambulances.”

Chief Randy Mellow, President of the Paramedic Chiefs of Canada and Chief of the Peterborough County/City Paramedics, said, “It is a certainty that the Paramedic community requires agility and adaptability to keep pace with the complexity and evolution of care as never seen before. The COVID-19 pandemic has demanded the attention of thoughtful leaders to reflect and refocus, to ensure that as the emergency services industry grows and evolves, so does the emerging knowledge and investment in high-risk infection control. The DBC Ambulance Decontamination white paper provides guiding principles, practical recommendations, and resources to help EMS organizations form strategies that will enhance safety for patients, responders, and our communities.”

The white paper is available in several versions including a U.S. and Canadian foreword, and French translation. Individuals or organizations interested in learning more about ambulance decontamination should visit DBCAmbulances.com or download a free copy now. For more information about the white paper, please contact Vanessa Bomboir, Marketing Manager for Demers-Braun-Crestline at (306) 986-5677 or vbomboir@crestlinecoach.com.

About Demers-Braun:

Demers Ambulances, Braun Ambulances, and Crestline Coach are three distinct brands owned by Demers-Braun. The second-largest ambulance manufacturing organization in North America, Demers-Braun has been recognized for leadership in innovative design and quality products. With over 140 years of combined history meeting the needs of customers in over 42 countries, Demers Ambulances, Braun Ambulances, and Crestline Coach offer a wide-range of ambulances, specialty vehicles, and small to mid-sized buses. To learn more about the respective brands, visit their websites at Demers-Ambulances.com, BraunAmbulances.com, CrestlineCoach.com, or CCL150.com.

Share article on social media or email:

With FIPS 140-2 Validation, Enovate Medical becomes the First Connected EHR Workstation on Wheels for Federal Government Networks


FIPS 140-2 Validated Certificate #3706

“We have a mission to support successful care for our veterans. Partnering with Enovate Medical allows us to bring a leading-edge EHR solution to the VA and DoD that also meets their security standards,” said Jason Goldberg, Four Points Technology Vice President.

Enovate Medical announced today that its hardware and software have completed the rigorous NIST (U.S. National Institute of Standards and Technologies) testing. Its products are now certified to connect to the Federal Government networks, including VA medical facilities and DoD installations. With Enovate’s Envoy and Encore EcoFlex clinical workstations on wheels and its cloud-based Rhythm asset management software platform passing the FIPS 140-2 security requirements, Enovate Medical is the only EHR workstation vendor to earn this recognition.

The VA and DoD Electronic Health Record (EHR) Modernization Program was established to develop the next-generation platform for a modern EHR infrastructure. This EHR modernization creates a need within the VA and DoD system for workstations on wheels that meet the government’s stringent security requirements.

“The VA and DoD are in the process of modernizing their EHR infrastructure,” explained Bob Brolund, CEO of Enovate Medical. “With any real-time EHR system, it is essential to have a robust digital security strategy in place – but until now, no clinical workstation on wheels vendor had received the Federal Government’s FIPS 140-2 certification. Enovate Medical is proud to have met these requirements.”

Secure architecture and secure data form the foundation of a modern EHR infrastructure. “Shortcuts aren’t acceptable where health data is concerned,” explained Mark Dalen, Enovate Medical’s CTO. “Our certified, secure cloud-based approach creates a complete separation between the veteran’s health information and the machine data required for operational efficiency. Enovate Medical invested a year’s effort to meet the FIPS 140-2 cryptography standards on sensitive data within the Federal Government.”

Enovate Medical partnered with Four Points Technology, a CVE-verified Service Disabled Veteran Owned Small Business, to deliver this EHR solution to the VA and DoD. “We have a mission to support successful care for our veterans. Partnering with Enovate Medical allows us to bring a leading-edge EHR solution to the VA and DoD that also meets their security standards,” said Jason Goldberg, Four Points Technology Vice President of Sales. “We’re excited about the operational and clinical benefits that Enovate Medical can introduce into the government healthcare space.”

To learn more about Enovate Medical’s FIPS 140-2 validated products, visit http://www.enovatemedical.com/federal

ABOUT ENOVATE MEDICAL

Enovate Medical manufactures and implements intelligent workstation on wheels solutions and services that improve clinical workflows and facilitate real-time Electronic Health Record (EHR) charting at the point of care.

Enovate’s mobile power solutions allow nurses to capture patient data uninterrupted throughout their shift. Our cloud-based monitoring of workstation on wheels, real-time location, and battery health maximizes the performance of IT and clinical teams. Enovate’s technology delivers fleet optimization programs to cut waste and drive down the overall cost of ownership.

Our consultative approach and a holistic view that integrates technology, service, and support, help our customers reduce costs, enhance productivity, and improve clinical outcomes.

For more information about Enovate Medical’s federal solutions, please visit http://www.enovatemedical.com/federal or contact Dawn Wilson, Content and Events Marketing Manager at 888-909-8906 extension 121.

ABOUT FOUR POINTS TECHNOLOGY

Four Points Technology is a CVE-verified Service-Disabled Veteran-Owned Small Business (SDVOSB) dedicated to providing IT products, professional services, and clinical solutions to the Federal Government. By leveraging well-established relationships with major vendors, suppliers, and partners, Four Points provides custom and leading-edge information technology solutions to meet customers’ unique needs. For more information about Four Points, please visit http://www.4points.com/.

Share article on social media or email:

Babyscripts Announces Commercial Partnership with Roche Diagnostics


News Image

Roche’s investment in Babyscripts solutions is a tremendous validation of our vision for improving maternal care, and an example of the kind of strategic collaboration essential to moving the needle on outcomes.

Babyscripts, the leading virtual care platform for managing obstetrics, today announced a commercial partnership with Roche Diagnostics, a division of the world’s largest biotech company and a global pioneer in pharmaceuticals and diagnostics. Roche Diagnostics and Babyscripts will collaborate on the next generation of digital and diagnostic combinations in women’s health.

Under the terms of this collaboration, Roche will partner with Babyscripts on the development of Babyscripts’ remote patient monitoring (RPM) programs to leverage groundbreaking data science through the next generation of RPM in pregnancy. These programs will be focused on solving issues of blood pressure-related complications through RPM, such as prenatal hypertension. Babyscripts participated in Startup Creasphere, Roche’s digital health accelerator program, which was instrumental in initiating this collaboration.

“Roche’s investment in Babyscripts solutions is a tremendous validation of our vision for improving maternal care, and an example of the kind of strategic collaboration essential to moving the needle on outcomes,” said Juan Pablo Segura, co-founder and President of Babyscripts. “Roche’s vast expertise in the field of women’s health diagnostics and clinical science combined with our on-the-ground experience in the virtual maternal health space is going to prove a game changer for rethinking how we approach prenatal and postpartum care.”

Roche has a long history of innovation in the women’s maternal health space, yielding a portfolio of fertility and prenatal tests that deliver highly accurate results, such as ElecsysⓇ AMH testing to help understand a women’s fertility status to improve chances of conception and HarmonyⓇ non-invasive prenatal testing that assesses the probability for trisomies 21, 18, 13. These advanced diagnostic and screening tests empower couples and clinicians to make decisions from pregnancy planning to birth. Through the collaboration with Babyscripts, Roche will continue their commitment to bringing innovative, data-driven and integrated solutions to pregnant and postpartum mothers.

Babyscripts has spent the last six years building a clinically-validated, virtual care platform to allow OBGYNs to deliver a new model of prenatal and postpartum care. Using internet-connected devices for remote monitoring, Babyscripts offers risk-specific experiences to allow providers to manage up to 90% of pregnancies virtually, allowing doctors to detect risk more quickly and automate elements of care.

About Babyscripts

Babyscripts is delivering a new model for prenatal and postpartum care that is transforming the way expectant mothers use technology to work with their healthcare providers. We’ve spent the last six years delivering the most-implemented mobile clinical solution for remote monitoring in pregnancy, with the mission to eliminate maternal mortality and improve access to care for all mothers. Babyscripts was named to the 2020 Digital Health 150, CB Insights’ annual ranking of the 150 most promising private digital health companies in the world. For more information on our virtual care solution and to request a demo, visit http://www.babyscripts.com.

Disclaimer: The Harmony Prenatal Test was developed by Ariosa Diagnostics, a CLIA-certified laboratory. As with other lab-developed tests, it has not been cleared or approved by the FDA and is not available for sale as an IVD in the US. Non-invasive prenatal testing (NIPT) based on cell-free DNA analysis is not diagnostic; results should be confirmed by diagnostic testing.”

Share article on social media or email: